Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Natalie McCormick

Showing results (51-60 of 60) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 60 results.
Arthritis & Rheumatology (Hoboken, N.J.)|April 12, 2023
Prediagnostic Glycoprotein Acetyl Levels and Incident and Recurrent Flare Risk Accounting for Serum Urate Levels: A Population-Based, Prospective Study and Mendelian Randomization AnalysisAmit D Joshi, Natalie McCormick, Chio Yokose, et al.
JAMA Network Open|April 21, 2023
Trends in Prevalence of Gout Among US Asian Adults, 2011-2018Chio Yokose, Natalie McCormick, Na Lu, et al.
JAMA Network Open|August 15, 2022
Racial and Sex Disparities in Gout Prevalence Among US AdultsNatalie McCormick, Na Lu, Chio Yokose, et al.
Diabetes Care|January 30, 2026
Gout-Related Medication Use After Initiating Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Gout and Type 2 Diabetes: Population-Based Target Trial Emulation StudiesNatalie McCormick, Nitzan Burrack, Chio Yokose, et al.
Nature Reviews. Rheumatology|March 13, 2024
The clinical benefits of sodium-glucose cotransporter type 2 inhibitors in people with goutChio Yokose, Natalie McCormick, Abhishek Abhishek, et al.
BMJ (Clinical Research Ed.)|October 30, 2024
Comparative effectiveness of sodium-glucose cotransporter-2 inhibitors for recurrent nephrolithiasis among patients with pre-existing nephrolithiasis or gout: target trial emulation studiesNatalie McCormick, Chio Yokose, Na Lu, et al.
Arthritis Care & Research|August 22, 2024
Prediagnostic Amino Acid Metabolites and Risk of Gout, Accounting for Serum Urate: Prospective Cohort Study and Mendelian RandomizationNatalie McCormick, Amit D Joshi, Chio Yokose, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|December 13, 2022
Interactions Between Genetic Risk and Diet Influencing Risk of Incident Female Gout: Discovery and Replication Analysis of Four Prospective CohortsKehuan Lin, Natalie McCormick, Chio Yokose, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|May 26, 2025
Comparative Cardiovascular Safety of Nonsteroidal Anti-Inflammatory Drug Versus Colchicine Use When Initiating Urate-Lowering Therapy Among Patients With Gout: Target Trial EmulationsChio Yokose, Natalie McCormick, Na Lu, et al.
Seminars in Arthritis and Rheumatism|April 24, 2024
Serum urate change among gout patients treated with sodium-glucose cotransporter type 2 inhibitors vs. sulfonylurea: A comparative effectiveness analysisChio Yokose, Greg Challener, Bohang Jiang, et al.
Pageof 6

Showing results (51-60 of 60) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 60 results.
Arthritis & Rheumatology (Hoboken, N.J.)|April 12, 2023
Prediagnostic Glycoprotein Acetyl Levels and Incident and Recurrent Flare Risk Accounting for Serum Urate Levels: A Population-Based, Prospective Study and Mendelian Randomization AnalysisAmit D Joshi, Natalie McCormick, Chio Yokose, et al.
JAMA Network Open|April 21, 2023
Trends in Prevalence of Gout Among US Asian Adults, 2011-2018Chio Yokose, Natalie McCormick, Na Lu, et al.
JAMA Network Open|August 15, 2022
Racial and Sex Disparities in Gout Prevalence Among US AdultsNatalie McCormick, Na Lu, Chio Yokose, et al.
Diabetes Care|January 30, 2026
Gout-Related Medication Use After Initiating Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Gout and Type 2 Diabetes: Population-Based Target Trial Emulation StudiesNatalie McCormick, Nitzan Burrack, Chio Yokose, et al.
Nature Reviews. Rheumatology|March 13, 2024
The clinical benefits of sodium-glucose cotransporter type 2 inhibitors in people with goutChio Yokose, Natalie McCormick, Abhishek Abhishek, et al.
BMJ (Clinical Research Ed.)|October 30, 2024
Comparative effectiveness of sodium-glucose cotransporter-2 inhibitors for recurrent nephrolithiasis among patients with pre-existing nephrolithiasis or gout: target trial emulation studiesNatalie McCormick, Chio Yokose, Na Lu, et al.
Arthritis Care & Research|August 22, 2024
Prediagnostic Amino Acid Metabolites and Risk of Gout, Accounting for Serum Urate: Prospective Cohort Study and Mendelian RandomizationNatalie McCormick, Amit D Joshi, Chio Yokose, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|December 13, 2022
Interactions Between Genetic Risk and Diet Influencing Risk of Incident Female Gout: Discovery and Replication Analysis of Four Prospective CohortsKehuan Lin, Natalie McCormick, Chio Yokose, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|May 26, 2025
Comparative Cardiovascular Safety of Nonsteroidal Anti-Inflammatory Drug Versus Colchicine Use When Initiating Urate-Lowering Therapy Among Patients With Gout: Target Trial EmulationsChio Yokose, Natalie McCormick, Na Lu, et al.
Seminars in Arthritis and Rheumatism|April 24, 2024
Serum urate change among gout patients treated with sodium-glucose cotransporter type 2 inhibitors vs. sulfonylurea: A comparative effectiveness analysisChio Yokose, Greg Challener, Bohang Jiang, et al.
Pageof 6